CX Institutional: BFH position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of CX Institutional on BFH, newest first. How the timeline and the estimate are built.
CX Institutional held 0 BFH shares at 2026-03-31 per its 13F-HR filed 2026-04-06.
the latest 13F is the newest step
- period ended2026-03-3113F 0 sharesChange vs previous 13F -45 shares
13F-HR 0001737089-26-000003 filed by CX Institutional
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2025-12-3113F 45 sharesChange vs previous 13F -361 shares
<0.01% of the 13F portfolio, value $3,000.
13F-HR 0001737089-26-000001 filed by CX Institutional
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-09-3013F 406 sharesChange vs previous 13F -101,641 shares
<0.01% of the 13F portfolio, value $23,000.
13F-HR 0001737089-25-000011 filed by CX Institutional
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F/A 102,047 sharesChange vs previous 13F +54,751 shares
0.2% of the 13F portfolio, value $5,829,000.
13F-HR/A 0001737089-25-000007 filed by CX Institutional
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 47,296 sharesChange vs previous 13F +46,979 shares
0.09% of the 13F portfolio, value $2,369,000.
13F-HR 0001737089-25-000005 filed by CX Institutional
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-12-3113F 317 sharesChange vs previous 13F not available
<0.01% of the 13F portfolio, value $19,356.
13F-HR 0001737089-25-000001 filed by CX Institutional
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).